For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...

Five years into her transformation-focused tenure, Walmsley says the global drugmaker is at last ready to deliver results. She completed the final step of that overhaul this summer, spinning off ...

At the Financial Times (FT) Global Pharma and Biotech Summit in London on 6 November, GSK CEO Emma Walmsley ... and I hope ...

(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley ... In an early gaffe that ...

It’s been two and a half years since Emma Walmsley took over as CEO of GlaxoSmithKline, and at the time was seen as the protégé of her predecessor Sir Andrew Witty. Coming from the consumer ...

Dame Emma Walmsley prides herself on her tenacity. It is something the GSK chief says she inherited from her late father, a vice-admiral in the Royal Navy. “I’m genetically blessed with ...

Speculation is mounting GlaxoSmithKline's CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a stake in ...

GSK could double its long-serving CEO Emma Walmsley’s pay packet to £21.6 million ($27.2 million) after admitting its boss's current pay didn’t reward her performance and would put off future ...

CEO Emma Walmsley says. Speaking at the CEO Times Summit in London, Walmsley highlights the U.K. pharmaceutical company's refocused R&D strategy, with investments concentrated in the U.K., U.S ...

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s first-on ...